Clinical Trial

A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-18.
Status change: Not Yet Recruiting → Recruiting 2025-11-18
Trial Details
NCT Number NCT06839066
Lead Sponsor Shanghai Henlius Biotech
Conditions Nasopharyngeal Carcinoma (NPC)
Enrollment 70 participants
Start Date 2025-04-02
Primary Completion 2026-11-22 (estimated)
Study Completion 2027-11-22 (estimated)
Updated on ClinicalTrials.gov 2025-11-24